Physician profile
Mark Robbins
NPI 1538256672
$1,801.76
in general payments reported to CMS, 2019-2025
12 companies · $19.37 in 2025
The $19.37 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $79.32 · 2021: $288 · 2023: $164 · 2024: $89.57 · 2025: $19.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $891.34 | 2019 | |
| Shockwave Medical, INC | $288.30 | 2021 | |
| Medtronic Vascular, INC. | $255.99 | 2019-2020 | |
| Boston Scientific Corporation | $93.09 | 2019 | |
| Amgen INC. | $78.62 | 2023-2025 | Repatha, Repatha |
| Inspire Medical Systems, INC. | $42.23 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $41.68 | 2023 | |
| Novartis Pharmaceuticals Corporation | $35.97 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.23 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $20.89 | 2023 | Camzyos |
| Baxter Healthcare | $15.29 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $15.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.